Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Literature
1.
2.
Liberale L, Montecucco F, Camici GG, Dallegri F, Vecchie A, Carbone F et al (2017) Treatment with proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors to reduce cardiovascular inflammation and outcomes. Curr Med Chem 24:1403–1416CrossRef
3.
Bonaventura A, Grossi F, Carbone F, Vecchie A, Minetti S, Bardi N et al (2019) Serum PCSK9 levels at the second nivolumab cycle predict overall survival in elderly patients with NSCLC: a pilot study. Cancer Immunol Immunother 68:1351–1358CrossRef
Metadata
Title
PCSK9 is a promising prognostic marker in patients with advanced NSCLC
Authors
Aldo Bonaventura
Francesco Grossi
Fabrizio Montecucco
Publication date
01-03-2020
Publisher
Springer Berlin Heidelberg
Published in
Cancer Immunology, Immunotherapy / Issue 3/2020
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-020-02485-z

Other articles of this Issue 3/2020

Cancer Immunology, Immunotherapy 3/2020 Go to the issue

Original Article

The repertoire of tumor-infiltrating lymphocytes within the microenvironment of oral squamous cell carcinoma reveals immune dysfunction

Acknowledgement

Acknowledgement to reviewers

Original Article

Mass cytometry defines distinct immune profile in germinal center B-cell lymphomas

Original Article

Immune checkpoint inhibitors combined with chemotherapy for the treatment of advanced pancreatic cancer patients

Letter to the Editors

PD-L1 expression levels should be considered when identifying risk factors in NSCLC patients treated with nivolumab

Original Article

The CD38low natural killer cell line KHYG1 transiently expressing CD16F158V in combination with daratumumab targets multiple myeloma cells with minimal effector NK cell fratricide
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits